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Anaplastic carcinoma is an aggressive tumor that frequently 
develops in old age, and although rare cases have been reported 
to occur at a young age, it is extremely rare before age 30.1 Al-
though anaplastic carcinoma is known to occur de novo, ana-
plastic transformation by dedifferentiation from a well-differen-
tiated thyroid carcinoma (WDTC) has been reported.2 We de-
scribe an anaplastic carcinoma in a young adult. This study met 
criteria for exemption from review from the institutional review 
board.
A 31-year-old man with a relapsed tumor that was diagnosed 
as an anaplastic carcinoma of the thyroid died of respiratory 
failure 4 months after diagnosis. Eight years previously, he had 
a thyroid tumor diagnosed as a diffuse sclerosing papillary thy-
roid carcinoma that was removed by total thyroidectomy with 
central compartment neck dissection (CCND) and right inter-
nal jugular neck dissection. He also received postoperative ra-
dioisotope treatment, but 5 years later the tumor relapsed in 
the left surgical site and was removed. The histologic features of 
the initial diagnosis, the first relapse, and the second anaplastic 
carcinoma as well as the immunohistochemical staining and 
BRAF mutation results were reviewed and a literature search 
was performed to understand the mechanism of the anaplastic 
transformation of the WDTC.
CASE REPORT
Clinical manifestation
At 23 years of age, our patient presented with a palpable neck 
mass with no other underlying disease. Sonographic findings re-
vealed an enlarged isoechoic mass (4×2.5×2.5 cm) with periph-
eral rim-like calcification in the right lobe of the thyroid. A pre-
operative diagnosis of papillary thyroid carcinoma was deter-
mined and a bilateral total thyroidectomy with CCND and right 
internal jugular neck dissection was performed. The pathologic 
diagnosis determined that the mass was a diffuse sclerosing vari-
ant of papillary thyroid carcinoma confined to the right thyroid 
parenchyma (Fig. 1A, B). The tumor metastasized to several 
lymph nodes on the right side of the neck and the following re-
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gional lymph nodes (8/30): level II (2/6), level III (2/13), level 
IV (3/10), and perithyroidal (1/1). Approximately 30 mCi of 
radioactive iodine (131I) was used for postoperative adjuvant 
treatment.
After 5 years, a tumor was found at the previous left surgical 
site. Excision of the left surgical site with left modified radical 
neck dissection and right level II and III selective node dissec-
tion were performed. Microscopic findings were similar to the 
previous primary thyroid carcinoma findings. The tumor had 
again metastasized to several lymph nodes on the left side of the 
neck and the following regional lymph nodes (8/33): right level 
II (0/3); left level II (1/9), level III (1/4), and level IV (4/15), and 
perithyroidal (2/2). Postoperatively, 200 mCi of radioactive io-
dine (131I) was administered and a daily dose of 200 µg of levo-
thyroxine was prescribed for adjuvant treatment. Even though 
the patient continued with treatment, the tumor recurred at the 
left surgical site and the tumor size increased.
At 31 years of age, the patient identified another newly devel-
oped, palpable small mass at the right postauricular area, which 
grew rapidly within a month. Radiologic examination revealed a 
pretracheal tumor and bilateral neck lymph node enlargement. 
Excision of the trachea with right modified radical neck node 
dissection and left level VI selective neck dissection was per-
formed. Histologic diagnosis of the pretracheal lesion deter-
mined that the lesion was an anaplastic thyroid carcinoma with 
a focal papillary carcinoma component, and the tumor metasta-
sized to the following bilateral lymph nodes (8/18): right level II 
(5/14) and level V (0/1) and left level VI (3/3). After surgery, the 
patient experienced dysphagia and dyspnea, and despite inten-
sive care for respiratory failure, he died 4 months later.
Histopathologic findings
The first surgical specimen was comprised of bilateral thy-
roid glands and lymph nodes. The right thyroid gland con-
tained a 4×2.5-cm ill-defined, yellow-tan mass. Histologically, 
the tumor showed typical papillary thyroid carcinoma features 
with lymphocytic thyroiditis, squamous morules, and abun-
dant psammoma bodies in the outside of the tumor. These 
findings are consistent with diffuse sclerosing papillary thyroid 
carcinoma.
The histologic findings of the recurred tumor showed a pat-
tern similar to the previous primary thyroid carcinoma. Our re-
view of this tumor histology revealed a focal (<5%) poorly dif-
ferentiated carcinoma component in the first recurrent papillary 
thyroid carcinoma of the left surgical site (Fig. 1C, D). We de-
fined a poorly differentiated carcinoma component as a tumor 
with 1) a focal solid pattern of growth, 2) absence of conven-
tional nuclear features of papillary carcinoma, and 3) presence of 
convoluted nuclei.3
The anaplastic carcinoma of the second recurrent tumor re-
vealed typical histologic findings: large pleomorphic, epitheli-
oid, spindle, and multinucleated giant tumor cells, abundant 
eosinophilic cytoplasm, pleomorphic nuclei, more than two 
prominent nucleoli, frequent mitosis, and focal tumor necrosis 
(Fig. 1E, F). The periphery of this anaplastic carcinoma showed 
a remnant of papillary carcinoma.
Immunohistochemical staining and BRAF mutation analysis
Immunohistochemical staining for thyroglobulin, galectin-3, 
thyroid transcription factor 1 (TTF-1), p53, and Ki-67 was per-
formed. The antibodies used in this study are shown in Table 1. 
Table 2 and Fig. 2 summarize the immunohistochemical stain-
ing results. Thyroglobulin showed diffuse, granular, cytoplasmic 
staining in the tumor cells of the initially diagnosed and re-
curred papillary thyroid carcinoma. These tumor cells were posi-
tive for galectin-3 and TTF-1 but negative for p53. Ki-67 ex-
pression was present in <1% of the initially diagnosed tumor 
cells and recurred papillary thyroid carcinoma. In the poorly dif-
ferentiated tumor carcinoma component of the first recurrent 
tumor, thyroglobulin, TTF-1, and galectin-3 expression was 
lower than in the other part of the first recurrent tumor, but p53 
and Ki-67 expression was the same. Thyroglobulin, TTF-1, and 
galectin-3 expression were decreased in the anaplastic carcinoma 
of the second recurrent tumor. However, nuclear p53 and Ki-67 
expression levels were 70% and 60% to 70%, respectively, of 
the anaplastic carcinoma component.
The BRAF gene mutation analysis of each tumor tissue per-
formed by a pyrosequencing method revealed BRAF gene mu-
tations in all tissues (Fig. 3). We defined the mutant allele peak 
of 5% to 95% as the optimal cutoff value.4 The BRAF V600E 
(c.1799T>A) and a low level of the BRAF V600V (c.1800G> 
A) mutation were found in the initially diagnosed papillary thy-
roid carcinoma and poorly differentiated carcinoma component 
of the recurred papillary thyroid carcinoma, but only the promi-
nent BRAF V600V (c.1800G>A) mutation was found in the 
anaplastic carcinoma component.
DISCUSSION
We report a rare case of anaplastic carcinoma in a young pa-
tient, analyze the follow-up pathology data related to anaplastic 
transformation, and discuss the mechanism of anaplastic trans-
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formation.
Anaplastic thyroid carcinoma occurs mainly in the elderly. 
The mean age of diagnosis is 55 to 65 years, with the peak inci-
dence in the sixth to seventh decade of life. Only 25% of pa-
tients are younger than 60 years at diagnosis. The age of most 
reported cases was more than 30 years, and only a few reported 
cases were younger than 30 years.1 Most reported cases of ana-
plastic transformation by dedifferentiation from a WDTC were 
in the elderly.5 Therefore, thorough clinical history of previous 






Fig. 1. (A, B) Papillary thyroid carcinoma at 23 years of age. (C, D) Recurrent papillary thyroid carcinoma after 5 years. Poorly differentiated 
cells are seen at focal areas of the papillary thyroid carcinoma. (E, F) Recurrent anaplastic thyroid carcinoma in the pretrachea adjacent thy-
roid bed.
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anaplastic transformation should be considered when a diagno-
sis of anaplastic carcinoma is confirmed in an elderly patient.
Anaplastic thyroid carcinoma is a highly aggressive neoplasm 
with a poor prognosis. The mortality rate is >90%, with a 
mean survival of 6 months after diagnosis.6 Almost all patients 
complain of a rapidly growing neck mass and symptoms associ-
ated with a large mass such as hoarseness, dysphagia, vocal cord 
paralysis, cervical pain, and dyspnea are the most frequent and 
important. The overall 5-year survival ranges from 0% to 14% 
and the median survival is 4 to 12 months. The enlarged tumor 
mass often causes death by obstruction or invasion of a vital 
structure, similar to the occurrence in our patient.6
Anaplastic thyroid carcinoma may arise de novo or, more com-
monly, through anaplastic transformation (or dedifferentiation) 
of a preexisting papillary or follicular thyroid carcinoma. The 
mechanism of this transformation, however, is not well under-
stood.5
In this study, we performed immunohistochemical staining 
and BRAF mutation analysis to determine the mechanism of 
anaplastic transformation in the WDTC, and we found that the 
well-expressed markers in the WDTC showed loss of expression 
in the anaplastic carcinoma. We also confirmed that the mark-
ers known to participate in transformation including p53, Ki-
67, and others were not initially expressed but were expressed 
at the full anaplastic transformation. Todd and Wenig7 reported 
that thyroglobulin and TTF-1 immunoreactivity was com-
pletely reduced in recurrent or metastatic thyroid carcinoma 
and anaplastic thyroid carcinoma, which showed less differenti-
ated histologic features, and these results were identical to the 
immunostaining results of our case. Ozaki et al.8 reported that 
high Ki-67 expression was found in more malignant tumors, 
which was also similar to the findings in our case. Many studies 
have examined the role of the p53 gene in the thyroid as well as 
other organs, and most of these studies have shown that a loss 
in p53 gene expression is related to malignant transformation. 
Furthermore, studies of the thyroid have reported to be related 
to anaplastic transformation in WDTC.9 The p53-positive 
staining that appears in the full anaplastic transformation of our 
case is similar to other reports. However, additional research is 
necessary to determine the stage of anaplastic transformation in 
which the change in p53 and Ki-67 expression appears.
Mutation of the BRAF gene represents the most common ge-
netic alteration in papillary thyroid cancer and is found in 45% 
of these tumors in Western countries and up to 90% of these tu-
mors in Korea.10 The vast majority of BRAF alterations in papil-
lary thyroid cancer are BRAF V600E mutations,10 but BRAF 
K601E mutations have been reported in both follicular and solid 
variants.11 In multifocal thyroid cancer, different tumor nodules 
have distinct genetic alterations, such as different types of RET/
PTC rearrangement or variation in the presence of the BRAF 
mutation.12 Recently, in Korea, Kim et al.11 reported BRAF mu-
tations that appeared in different forms according to the histo-
logic subtype in a multifocal papillary carcinoma. Because the 
conventional papillary carcinoma component in their patient re-
vealed the BRAF V600E mutation, but the follicular variant 
component revealed the BRAF K601E mutation, they deter-
mined that the multifocal papillary carcinoma occurred de novo 
rather than as a result of intrathyroid metastasis, although no 
clear classification can be determined yet. In our case, the BRAF 
V600E and BRAF V600V mutations were found in the initially 
diagnosed papillary thyroid carcinoma and the poorly differenti-
ated carcinoma component of the recurred papillary thyroid car-
cinoma, but only the BRAF V600V mutation was found in the 
anaplastic carcinoma component. However, there has not been 
any report of a BRAF V600V (c.1800G>A) mutation in thy-
roid carcinoma. We found two reports of a BRAF V600V muta-
tion in malignant melanoma13 and colorectal cancer,14 but the 
reports did not attempt to explain the relevance of the BRAF 
V600V mutation expression. We found that the BRAF muta-
Table 1. Panel of antibodies used in this study
Antibody            Source   Clone   Dilution
Thyroglobulin Dako (Carpinteria, CA, USA) A251 1:10,000
Ki-67 Dako (Carpinteria, CA, USA) M7240 1:150
TTF-1 Dako (Carpinteria, CA, USA) M3575 1:200
Galectin-3 NovoCastra 
   (Newcastle Upon Tyne, UK)
NCL-GAL3 1:50
p53 NovoCastra 
   (Newcastle Upon Tyne, UK)
D02 1:300
TTF-1, thyroid transcription factor 1.









Thyroglobulin + (80) + (80) + (30) + (<5)
Galectin-3 + (95) + (95) + (60) + (50)
TTF-1 + + - - 
p53 - - - + (70)
Ki-67 + (<1) + (<1) + (<1) + (60-70)
BRAF V600E
   (c.1799T>A)
+ Not done + - 
BRAF V600V
   (c.1800G>A)
+ Not done + + 
Values in parentheses indicate percentage.
WDTC, well differentiated thyroid carcinoma; PDC, poorly differentiated 
carcinoma; TTF-1, thyroid transcription factor 1.
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Fig. 2. Immunohistochemical staining for thyroglobulin, galectin-3, thyroid transcription factor 1 (TTF-1), p53, and Ki-67. Initially diagnosed 
and recurred well-differentiated thyroid carcinoma (WDTC) show diffuse positivity for thyroglobulin (TG), galectin-3, and TTF-1 but is negative 
for p53 and less than 1% of Ki-67 expression. In the poorly differentiated tumor carcinoma (PDC) component of the first recurrent tumor, 
thyroglobulin, TTF-1, and galectin-3 expression are lower than in the other part of the first recurrent tumor, but p53 and Ki-67 expression are 
the same. Thyroglobulin, TTF-1, and galectin-3 expression is decreased in the anaplastic carcinoma of the second recurrent tumor. Howev-
er, nuclear p53 and Ki-67 expression are 70% and 60% to 70%, of the anaplastic carcinoma component, respectively. PDC, poorly differen-
tiated carcinoma; ATC, anaplastic thyroid carcinoma; H&E, hematoxylin and eosin.
tion type changed during the tumor relapse process, but addi-
tional research is necessary to determine whether the alteration 
of the BRAF mutation is just an incidental finding or a pheno-
typic change relevant to the anaplastic transformation.
In conclusion, we evaluated the rare occurrence of anaplastic 
carcinoma in young patients and did not find p53 or Ki-67 ex-
pression or decreased thyroglobulin, TTF-1, and galectin-3 ex-
pression in the poorly differentiated tumor cells. Thyroglobu-
lin, TTF-1, and galectin-3 were well expressed in the WDTC. 
Therefore, we considered the possibility that overexpression of 
p53 and Ki-67 contributed to the anaplastic transformation. 
Additional studies are necessary to ascertain the intermediate 
steps of anaplastic transformation. If the markers that are well 
manifested in WDTC are lost even though p53 and Ki-67 are 
not expressed, then we can consider those changes in expression 
as precursors to anaplastic transformation. Therefore, future 
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Fig. 3. BRAF gene mutation analysis of each tumor tissue by pyrosequencing. The BRAF V600E (c.1799T>A) and a low level of the BRAF 
V600V (c.1800G>A) mutation are found in the initially diagnosed papillary thyroid carcinoma (A) and poorly differentiated carcinoma compo-
nent of the recurred papillary thyroid carcinoma (B), but only a prominent BRAF V600V (c.1800G>A) mutation is found in the anaplastic car-
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studies with thorough and careful histologic examination may 
allow us to predict the anaplastic transformation of the tumor.
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